SOMAÍ launches Thailand’s Iridescent Med in the UK

SOMAÍ has brought Thai medical cannabis brand Iridescent Med into the UK, marking the brand’s first move into Europe and expanding SOMAÍ’s pharmaceutical cannabis portfolio. The launch puts a female-founded, indoor-grown flower brand into UK pharmacy channels through SOMAÍ’s supply chain and wholesaler Hologram.

Why it matters: - SOMAÍ is expanding its European medical cannabis business with a brand that adds female leadership, Thai cultivation expertise, and indoor-grown flower to its portfolio. - The launch brings Iridescent Med into the UK market through pharmacy distribution, giving prescribers and patients another pharmaceutical-grade option. - The move also marks Iridescent Med’s first entry into the European medical cannabis market.

What happened: - SOMAÍ announced the UK launch of Iridescent Med on September 22, 2026. - Iridescent Med was founded and is led by Siratcha “Min” Patcharasopachai. - The brand is described as one of Thailand’s best-known and most trusted cannabis brands. - SOMAÍ is distributing Iridescent Med through its existing pharmaceutical supply chain and pharmacy network. - Hologram, an independent wholesaler, is distributing the product to pharmacies in the UK.

The details: - Iridescent Med grows indoor flower under GACP-certified cultivation standards. - The brand’s facility uses precision environmental control, ISO Class 8 cleanroom standards, in-house genetics development, and quality systems. - SOMAÍ described itself as an EU-GMP-certified, vertically integrated multi-country operator focused on cannabinoid-based medicines. - SOMAÍ said its portfolio includes EU GMP-certified cannabinoid pharmaceutical extracts and flower. - SOMAÍ owns SOMAÍ Pharmaceuticals and NovaSoma, its indoor cultivation site in Lisbon, Portugal. - The company said it continues to pursue acquisitions and global brand partnerships.

Between the lines: - The partnership links a Thai medical cannabis brand with a European pharmaceutical distribution platform at a time when both markets are growing. - Iridescent Med’s positioning emphasizes medicine-style consistency, traceability, and purity rather than consumer cannabis branding. - The launch also highlights a rare combination in the sector: a female-founded Asian brand entering Europe through a regulated supply chain. - Michael Sassano, SOMAÍ founder and interim CEO, said the brand stood out for “clean-room cultivation” and “real certification.”

What’s next: - Iridescent Med will now be available through UK pharmacy channels supported by Hologram. - SOMAÍ appears to be continuing its push for additional international partnerships and portfolio growth. - The launch could set up further expansion for Iridescent Med beyond the UK as SOMAÍ deepens its European reach.

The bottom line: - SOMAÍ is using Iridescent Med to broaden its European cannabis footprint with a premium Thai brand built for medical markets, not recreational ones.